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INTRODUCTION
Atopic diseases, being relatively rare until a few 
decades ago, are a serious health, economic and so-
cial problem. According to World Health Organiza-
tion (WHO) allergic diseases affect more than 40% 
of the population in developed countries (15). About 
10% of children and 25% of adults suffer from aller-
gic diseases. Publication data show that prevalence of 
AR in children is between 20 to 30% (4). The per-
centage of pediatric patients with asthma grows rap-
idly, in some of the developed countries reaching up 
to 15%, and in some regions, social strata and ethnic 
groups exceeding 20% (11).
ABSTRACT
Epidemiological studies on respiratory allergies have shown that allergic rhinitis (AR) and bronchial asth-
ma (BA) often coexist in the same patient. The premise “one respiratory system, one disease” marks a change 
in diagnostic and therapeutic treatment of respiratory allergies. Allergic Rhinits and Its Impact on Asthma-
ARIA Initiative at WHO aims to spread, educate and implement evidence-based management of allergic rhi-
nitis as a risk factor for development of asthma worldwide. This study reviews current concepts and trends 
in the management of respiratory allergies in compliance with the recommendations of ARIA.
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Studies show that 87% of children with asth-
ma suffer from allergic rhinitis, and patients with al-
lergic rhinitis are at three times higher risk than the 
general population of developing asthma (18). The 
concept of a continuous airway views allergic rhini-
tis and asthma as a manifestation of the same patho-
logical process – an allergic inflammation (2). Undi-
agnosed and untreated, AR increases the risk of de-
velopment of asthma by about three times, adversely 
affects asthma attacks and increases the likelihood of 
hospitalization by 50%. Proper treatment and control 
of AR can improve BA and reduce the risk of its de-
velopment (16). Through АRIA (Allergic Rhinits and 
Its Impact on Asthma) Initiative, WHO educates and 
provides guidelines for treatment of AR to prevent its 
progression to asthma.
SEVERITY ASSESSMENT OF ALLERGIC 
RHINITIS 
АRIA introduces a new classification, dividing 
AR into “intermittent” and “persistent” and replac-
ing the previously used division of rhinitis into sea-
sonal and perennial. Intermittent AR is defined by 
symptoms that occur for up to 4 days per week, not 
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more than 4 consecutive weeks, whereas persistent 
AR lasts for more than 4 days per week and for more 
than 4 consecutive weeks. Based on severity of symp-
toms and the degree to which they affect the patient’s 
quality of life, allergic rhinitis is classified as mild or 
moderate-severe (5) (Fig.1).
ARIA classification reflects the condition of the 
patient and serves as basis for determination of AR 
treatment and evaluation of its control (16).
A study of over 3000 AR patients consulting 
general practitioners demonstrated that 93% of the 
patients had a diagnosis of moderate-to-severe rhi-
nitis and the remaining 7% - a diagnosis of mild rhi-
nitis (7).
TREATMENT OF AR ACCORDING TO ARIA 
GUIDELINES 
Behavior in allergic rhinitis based on ARIA and 
WHO Guidelines includes: avoidance of contact with 
the specific allergen (allergens) or with precipitating 
factors, pharmacological therapy, immunotherapy, 
patient education (20) (Fig. 2).
Allergen removal is recommended whenev-
er possible. In recent years, nasal irrigations with a 
saline solution are more and more often used. They 
provide mechanical removal of the allergen and 
moisturizing and have a decongestant effect. 
PHARMACOTHERAPY 
A wide spectrum of medications is available 
for the treatment of allergic rhinitis. Therapy can 
be tailored to specific clinical symptoms, treatment 
regimen can involve a single medication or multi-
ple medications, depending on the severity of symp-
toms. Combining medications of different classes 
is effective, as they influence inflammatory mech-
anisms differently. Antihistamines and intranasal 
corticosteroids are the treatment of choice in patients 
with moderate to severe symptoms. Once symptoms 
are controlled, the number of medications can be re-
duced to a single agent (5). The agents used to treat al-
lergic rhinitis include antihistamines, decongestants, 
corticosteroids, mast cell stabilizers, anticholinergic 
agents, leukotriene receptor antagonists and immu-
notherapy (20).
Antihistamines 
Although antihistamines are effective in the 
treatment of allergic rhinitis, the use of first gener-
ation antihistamines (Chlorpheniramine, Clemas-
tine, Diphenhydramine, Ketotifen) has been limit-
ed by adverse effects due to lack of selectivity for the 
H1 receptor and propensity to cross the blood-brain 
barrier (14). Second generation antihistamines (Ce-
tirizine, Loratadine, Fexofenadine, Levocetirizine, 
Desloratadine) are developed to increase the selectiv-
ity for the H1 receptor and eliminate anticholiner-
gic and sedative side effects inherent to first gener-
ation agents. According to ARIA, oral or local non-
sedating H1 blockers are recommended as first-line 
therapy in all forms of allergic rhinitis regardless of 
clinical symptom severity (20). According to studies, 
long-term antihistamine treatment of patients with 
persistent AR significantly reduces the incidence of 
asthma episodes and the need of administration of 
asthma attack medications (19).
Decongestants 
Decongestants come in oral and intranasal 
form. Long-term use of oral decongestants (Ephed-
rine, Phenylephrine, Phenylpropanolamine, Pseudo-
ephedrine) is undesirable because of their side effects: 
Fig. 1. Classification of allergic rhinitis according to ARIA 
(2)
Fig. 2. ARIA Guidelines for the Treatment of Allergic  
Rhinitis (20)
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nervousness, insomnia, irritability, headache, in-
creased blood pressure, heart palpitations and tachy-
cardia. Nasal decongestants (Epinephrine, Naphazo-
line, Oxymethazoline, Xylomethazoline) provide 
faster and more powerful congestion relief compared 
to oral. Their long-term use is not recommended be-
cause of the risk of causing irreversible damage to na-
sal mucous membranes (2).
Intranasal Corticosteroids 
Because of the broad anti-inflammatory activ-
ity of nasal corticosteroids (Fluticasone, Beclometh-
asone, Budesonide, Mometasone, Ciclesonide), they 
are highly effective in the treatment of allergic rhi-
nitis. They are recommended as first-line therapy 
for intermittent moderate to severe allergic rhinosi-
nusitis and persistent allergic rhinitis (2). Compared 
with antihistamines and cromolyns, intranasal cor-
ticosteroids have a powerful effect on sneezing and 
nasal congestion. Maximum effect is achieved after 
prolonged use. When given before the allergy season, 
intranasal corticosteroids can prevent symptoms or 
reduce their severity. Nasal corticosteroids are con-
sidered safe. The most common adverse effect is epi-
staxis, which can occur in up to 10% of patients (17).
Mast Cell Stabilizers (Chromones) 
Although chromones (Sodium cromoglycate, 
Nedocromil) help control the symptoms of allergic 
rhinitis and their safety profile is excellent, the use 
of Sodium cromoglycate or nedocromyl is limited. 
Their therapeutic effect is less pronounced compared 
to other medications and in severe symptoms treat-
ment with them is not effective enough. Chromones 
require dosing four times daily, making patient com-
pliance difficult. Chromones are more effective if 
given before exposure to the allergen, for example, 
with preseasonal treatment  (2).
Leukotriene Receptor Antagonists (Montelu-
kast, Pranlukast, Zafirlukast) 
These medications were used initially in the 
treatment of bronchial asthma, but they also have 
demonstrated efficacy in treating allergic rhinitis. 
Their efficacy is similar or slightly less than that of 
antihistamines and significantly less than that of in-
tranasal corticosteroids (13). The main indications 
for use are in patients who are unable to use intra-
nasal corticosteroids or antihistamines or as an ad-
ditional medication for patients whose allergic rhini-
tis is not sufficiently controlled with intranasal cor-
ticosteroids. In many cases, in patients with mild to 
moderate-severe persistent asthma and allergic rhi-
nitis, they are preferred as monotherapy (8).
ALLERGEN-SPECIFIC IMMUNOTHERAPY
Allergen specific immunotherapy interferes 
with the basic mechanisms of the allergy and alters 
the natural course of allergic diseases, resulting in 
symptomatic relief and offering the patient a long-
lasting and preventive effect. These are observed us-
ing both subcutaneous and sublingual routes. Sub-
cutaneous immunotherapy was shown to reduce 
the onset of new sensitisations as well as the devel-
opment of asthma in patients with allergic rhinitis 
(10,15). Immunotherapy is now recognised as com-
plementary to the pharmacological treatment for re-
spiratory allergy. It is suggested that immunotherapy 
should be initiated early in the course of the disease, 
when irreversible damages are not yet established 
and when it is still possible to modify the progression 
of the disease. However, it is usual to start this treat-
ment after the age of 5.
PATIENT EDUCATION 
It has been found that low public awareness of 
allergies as serious chronic disease is a major issue. 
Patients suffering from respiratory allergies are not 
fully aware of the importance of the management of 
allergies and the implications accompanying their 
progression. Patients, especially those with mild al-
lergies tend to adapt to their symptoms or resort to 
self-medication without consulting the doctors (3). 
According to data published, in Europe only 45% of 
patients with allergic rhinitis seek medical advice or 
treatment of their disease (6). Patients should be ed-
ucated to avoid exposure to allergens and other pre-
cipitating factors, for possible side effects of therapy 
(medications and immunotherapy), allergic rhinitis 
complications and its impact on asthma.
PHARMACIST’S ROLE AS A CONSULTANT 
TO HELP PATIENTS WITH RESPIRATORY 
ALLERGIES 
The key to effective treatment and control of re-
spiratory allergies is collaboration between patients, 
pharmacists and health care professionals. Allergy is 
a disease that should be monitored even in the ab-
sence of exacerbations. Pharmaceutical care includes 
consultations, prevention, monitoring and evalu-
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ation of treatment (9). In accordance with ARIA 
guidelines (1) pharmacists play role in:
 ❖ Recognizing allergic rhinitis and distinguishing 
it from other conditions, including infections 
 ❖ Assessing AR severity 
 ❖ Selling OTC medications and advising patients 
with intermittent and mild persistent AR where 
it is possible to achieve control 
 ❖ Referring patients with uncontrolled and per-
sistent severe AR to a physician 
Fig. 3 shows the pharmacist’s approach in ad-
vising patients with allergic rhinitis according to 
АRIA guidelines. 
To prevent allergic rhinitis exacerbations, phar-
macists should render services that ensure the prop-
er use of medications, the optimal therapeutic out-
come and the prevention of adverse drug reactions. 
This should be implemented through the collabora-
tive efforts of pharmacists, physicians and patients. 
As a reliable source of medical information and 
advice, pharmacists play a crucial role in the self-
medication of patients with intermittent and persis-
tent allergic rhinitis, whose symptoms can be effec-
tively controlled. Antihistamines are often used in-
discriminately and without the supervision of a phy-
sician because of their OTC drug status. This under-
scores the importance of patient counselling provid-
ed by pharmacists.
Moreover, pharmacists should be able to recog-
nize the different types of allergic rhinitis in order 
to recommend an appropriate treatment with OTC 
drugs. Patients with uncontrolled severe persistent 
allergic rhinitis should be referred to a physician.
According to ARIA in the Pharmacy, patients 
with allergic rhinitis should be questioned and mon-
itored for symptoms of concomitant asthma. If un-
diagnosed or uncontrolled BA is suspected, they 
should be referred to a specialist physician (1).
DISCUSSIONS
Regardless of the accumulation of knowledge 
and clinical experience, allergic rhinitis remains a 
hypo-diagnosed disease. Persistent AR is often con-
cealed from acute and chronic rhinosinusitis, otitis, 
bronchial asthma. 
Timely treatment of allergic rhinitis should be 
deemed an important element of the treatment and 
control of bronchial asthma and an essential part of 
asthma prevention.
Being the most accessible source of health in-
formation, pharmacists have to meet the constant-
ly increasing requirements of modern healthcare 
systems.
The aim of pharmacy practice is to contrib-
ute to public health improvement by providing pa-
tient counselling and advice on disease prevention, 
pharmacovigilance, health monitoring and an ade-
quate disease therapy. Pharmacists’ skills and com-
petence in the contemporary society can ensure op-
timal drug use, higher efficacy of pharmacotherapy 
and a reduction in healthcare systems’ costs.
CONCLUSION
An essential part of pharmacists’ responsibili-
ties is the implementation of effective pharmaceuti-
cal care. The introduction of additional training pro-
grams and the constant updating of pharmacists’ 
skills and competence are essential for the active par-
ticipation of healthcare professionals in the preven-
tion and treatment of respiratory allergies.
Early diagnosis and adequate management in 
cooperation with patients, medical and health pro-
fessionals can improve the quality of life of the pa-
tients and influence the frequency and severity of 
comorbid pathology.
Fig. 3. Selection of allergic rhinitis treatment by 
pharmacists (1)
58 
Scripta Scientifica Pharmaceutica, vol. 1, No. 2, 2014, pp. 54-58
Copyright © Medical University of Varna
Allergic rhinits and its impact on asthma – aria. Control and prevention of respiratory allergies in pharmacy practice
REFERENCES
1. ARIA Pocket Guide for Pharmacists. In Edition 
2003.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Aller-
gic rhinitis and its impact on asthma, J Allergy Clin 
Immunol, 2001;108(5 Suppl):147–334.
3. Bousquet J, Van Cauwenberge P, Khaltaev N. Aller-
gic rhinitis and its impact on asthma (ARIA)- Ex-
ecutive summary. Allergy, 2003;57:841–855.
4. Bjorksten B, Clayton T, Ellwood P, Stewart A, Stra-
chan D. Worldwide timetrends for symptoms of 
rhinitis and conjunctivitis: Phase III of the Inter-
national Study of Asthma and Allergies in Child-
hood. Pediatr. Allergy Immunol., 2008;19:110-124.
5. Brozek JL, Bousquet J, Baena-Cagnani CE et al. Al-
lergic Rhinitis and its Impact on Asthma (ARIA) 
guidelines: 2010 revision. J Allergy ClinImmunol, 
2010;126,466-476.
6. Canonica GW, Bousquet J, Mullol J et al. A survey 
of the burden of allergic rhinitis in Europe. Allergy, 
2007;62(Suppl 85), 17-25.
7. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Pas-
salacqua G, Pallestrini E et al. Seasonal and peren-
nial allergic rhinitis: is this classification adherent 
to real life? Allergy, 2005;60:882–887.
8. Currie G, Devereux G, Lee D et al. Recent devel-
opments in asthma management. British Medical 
Journal, 2005;330:585-589.
9. Dessing RP. Ethics applied to pharmacy practice. 
Pharm World Sci, 2000;22:10–16.
10. Di-Rienzo V, Marcucci F, Puccinelli P, et al. 
Long-Lastingeffect of sublingual immunother-
apy in children with asthma due to house dust 
mite: a 10-year prospective study. ClinExpAllergy, 
2003;33:206–210. 
11. Ellwood P, Asher MI, Beasley R, Clayton TO, Stew-
art AW, the ISAAC Steering Committee. The inter-
national study of asthma and allergies in childhood 
(ISAAC): Phase Three rationale and methods. Int J 
Tuberc Lung Dis, 2005;9(1):10-6.
12. Marshal GD: Internal and external environmen-
tal influences in allergic diseases. J Am Ostheopath 
Assoc 2004;104:51-56.
13. Meltzer E, Malmstrom K, Lu S, et al. Concomitant 
montelukast and loratadine as treatment for sea-
sonal allergic rhinitis: placebo-controlled clinical 
trial. J Allergy Clin Immunol, 2000;105:917–922.
14.   Milgrom H, Bender B, Wamboldt F. Of injuries 
and antihistamines and dosing. Ann Allergy  Asth-
ma Immunol 2002;89:221–223.
15. Moller C, Dreborg S, Ferdousi HA, et al. Pol-
len immunotherapy reduces the development of 
asthma in children with seasonal rhinoconjunc-
tivitis (thePATstudy). J Allergy Clin Immunol, 
2002;109:251–256.
16. Pawankar R, Canonica G, Holgate S, Lockey R. 
WAO White Book on Allergy 2011-2012. In Edition 
Milwakee, Wisconsin, USA: WAO 2011.
17. Plaut M and Valentine MD. Clinical practice: aller-
gic rhinitis. N. Engl. J. Med., 2005;353:1934–1944.
18. Thomas M, Kocevar VS, Zhang Q et al: Asthma 
related healthcare resourse use among asthmat-
ic children with and without concomitant allergic 
rhinitis. Pediatrics, 2005;115: 129-134. 
19. www.eaaci.net/site/homepage.php - EAACI – Eu-
ropean Academy of Allergology and Clinical 
Immunology.
20. www.whiar.com – Allergic Rhinits and Its Impact 
on Asthma (ARIA).
